Abstract
Prostate-specific membrane antigen (PSMA) is a cell surface protein that is overexpressed in prostate cancer. Due to the specificity of expression of PSMA, numerous urea-based ligands have been synthesized until now. In the current study, we describe the coupling of the chelator desferrioxamine to DUPA-Pep and the subsequent labelling with Ga-68 and Zr-89 as new PSMA ligands. The labelling step is performed at room temperature and pH 7.5. In both radiosyntheses, the RCYs were higher than 95 % within 10 min, making dispensable any further purification and providing the radiotracers directly applicable for further utilization.
Similar content being viewed by others
References
David A, Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3(1):81–85
Dangshe MA, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC (2006) Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12(8):2591–2596
Olson WC, Heston WDW, Rajasekaran AK (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trial 2(3):182–190
Hao G, Zhou J, Guo Y, Long MA, Anthony T, Stanfield J, Hsieh J-T, Sun X (2011) A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. Amino Acids 41:1093–1101
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022–4028
Kularatne SA, Wang K, Santhapuram H-KR, Low PS (2009) Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 6(3):780–789
Kularatne SA, Venkatesh C, Santhapuram H-KR, Wang K, Vaitilingam B, Henne WA, Low PS (2010) Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem 53(21):7767–7777
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645–7653
Malik N, Machulla H-J, Solbach C, Winter G, Reske SN, Zlatopolskiy B (2011) Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep). Appl Radiat Isot 69(7):1014–1018
Malik N, Zlatopolskiy B, Machulla H-J, Reske SN, Solbach C (2012) One pot radiofluorination of a new potential PSMA ligand [Al18F]NOTA-DUPA-Pep. J Label Compd Radiopharm 55:320–325
Al-Momani E, Malik N, Machulla H-J, Reske SN, Solbach C (2013) Radiosynthesis of [18F]FEt-Tyr-urea-Glu ([18F]FEtTUG) as a new PSMA ligand. J Radioanal Nucl Chem 295(3):2289–2294
Wängler C, Wängler B, Lehner S, Elsner A, Todica A, Bartenstein P, Hacker M, Schirrmacher R (2011) A universally applicable 68Ga-labeling technique for proteins. J Nucl Med 52:586–591
Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, van Kiefer GE, Dongen GA (2010) p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 37:250–259
Ramogida CF, Orvig C (2013) Tumour targeting with radiometals for diagnosis and therapy. Chem Commun 49:4720–4739
Brechbiel MW (2008) Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging 52(2):166–173
Wadas TJ, Wong EH, Weisman GR, Anderson CJ (2010) Coordinating radiometals of copper, gallium, indium, yttrium and zirconium for PET and SPECT imaging of disease. Chem Rev 110(5):2858–2902
Solbach C, Bertram J, Scheel W, Baur B, Machulla H-J, Reske SN (2013) Production of Zr-89 on a PETtrace cyclotron. J Nucl Med 54(Suppl 2):1098
Holland JP, Phil D, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36(7):729–739
Meyer GJ, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M (2004) 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 31:1097–1104
Jackson GE, Byrne MJ (1996) Metal ion speciation in blood plasma: gallium-67-citrate and MRJ contrast agents. J Nucl Med 37:379–386
Acknowledgments
The project was supported by funding of the German Ministry of Economy and Technology (ZIM, Zentrales Innovationsprogramm Mittelstand) with a research grant. In addition we like gratefully to acknowledge the funding of the University of Milano-Bicocca (Milan, Italy) through a PhD fellowship in Biomedical Technology.
Author information
Authors and Affiliations
Corresponding author
Additional information
Benjamin Baur and Elena Andreolli contributed equally to this work.
Rights and permissions
About this article
Cite this article
Baur, B., Andreolli, E., Al-Momani, E. et al. Synthesis and labelling of Df-DUPA-Pep with gallium-68 and zirconium-89 as new PSMA ligands. J Radioanal Nucl Chem 299, 1715–1721 (2014). https://doi.org/10.1007/s10967-013-2876-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-013-2876-1